Literature DB >> 16570104

How many sites of action for endocannabinoids to control energy metabolism?

U Pagotto1, C Cervino, V Vicennati, G Marsicano, B Lutz, R Pasquali.   

Abstract

The promising results obtained by clinical trials using Rimonabant to tackle visceral obesity and related disorders recently promoted a remarkable impulse to carry out detailed investigations into the mechanisms of action of endocannabinoids in regulating food intake and energy metabolism. The endocannabinoid system has been known for many years to play an important role in the modulation of the neuronal pathways mediating the rewarding properties of food. However, in the last few years, with the advanced understanding of the crucial role of the hypothalamic neuronal network in the regulation of appetite, several studies have also directed attention to the orexigenic role of the endocannabinoid system, substantiating the well known appetite stimulating properties of derivatives of Cannabis sativa. Furthermore, the last 2 years have seen a number of relevant publications emphasizing the role of endocannabinoids as significant players in various peripheral metabolic processes. To date, the roles of the endocannabinoid system in influencing energy metabolism have proved to be more complex than was formerly believed. However, the diverse ability to modulate both central and peripheral processes highlights the pivotal involvement of the endocannabinoid system in the control of metabolic processes. This review describes the roles of endocannabinoids and the cannabinoid type 1 receptor (CB1) in the control of energy balance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570104     DOI: 10.1038/sj.ijo.0803277

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  10 in total

Review 1.  The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives.

Authors:  Theodore Garland; Heidi Schutz; Mark A Chappell; Brooke K Keeney; Thomas H Meek; Lynn E Copes; Wendy Acosta; Clemens Drenowatz; Robert C Maciel; Gertjan van Dijk; Catherine M Kotz; Joey C Eisenmann
Journal:  J Exp Biol       Date:  2011-01-15       Impact factor: 3.312

2.  A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.

Authors:  Nicole P Bowles; Ilia N Karatsoreos; Xiaosong Li; V Kiran Vemuri; Jodi-Anne Wood; Zhiying Li; Kellie L K Tamashiro; Gary J Schwartz; Alexandros M Makriyannis; George Kunos; Cecilia J Hillard; Bruce S McEwen; Matthew N Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

3.  Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice.

Authors:  Jesse LoVerme; Andrea Duranti; Andrea Tontini; Gilberto Spadoni; Marco Mor; Silvia Rivara; Nephi Stella; Cong Xu; Giorgio Tarzia; Daniele Piomelli
Journal:  Bioorg Med Chem Lett       Date:  2008-12-24       Impact factor: 2.823

4.  CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats.

Authors:  Emily E Thompson; Julia E Jagielo-Miller; V Kiran Vemuri; Alexandros Makriyannis; Peter J McLaughlin
Journal:  J Psychopharmacol       Date:  2016-03-22       Impact factor: 4.153

Review 5.  Translational models of cannabinoid vapor exposure in laboratory animals.

Authors:  Catherine F Moore; Jeffrey W Stiltner; Catherine M Davis; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2022-04-01       Impact factor: 2.293

6.  The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity.

Authors:  José María Moreno-Navarrete; Victoria Catalán; Lauren Whyte; Adenis Díaz-Arteaga; Rafael Vázquez-Martínez; Fernando Rotellar; Rocío Guzmán; Javier Gómez-Ambrosi; Marina R Pulido; Wendy R Russell; Mónica Imbernón; Ruth A Ross; María M Malagón; Carlos Dieguez; José Manuel Fernández-Real; Gema Frühbeck; Ruben Nogueiras
Journal:  Diabetes       Date:  2011-12-16       Impact factor: 9.461

7.  Daytime-Dependent Changes of Cannabinoid Receptor Type 1 and Type 2 Expression in Rat Liver.

Authors:  Ivonne Bazwinsky-Wutschke; Alexander Zipprich; Faramarz Dehghani
Journal:  Int J Mol Sci       Date:  2017-08-24       Impact factor: 5.923

8.  The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.

Authors:  Marcos F Fondevila; Uxia Fernandez; Maria J Gonzalez-Rellan; Natalia Da Silva Lima; Xabier Buque; Agueda Gonzalez-Rodriguez; Cristina Alonso; Marta Iruarrizaga-Lejarreta; Teresa C Delgado; Marta Varela-Rey; Ana Senra; Vera Garcia-Outeiral; Eva Novoa; Cristina Iglesias; Begoña Porteiro; Daniel Beiroa; Cintia Folgueira; Marta Tojo; Jorge L Torres; Lourdes Hernández-Cosido; Óscar Blanco; Juan Pablo Arab; Francisco Barrera; Diana Guallar; Miguel Fidalgo; Miguel López; Carlos Dieguez; Miguel Marcos; Maria L Martinez-Chantar; Marco Arrese; Carmelo Garcia-Monzon; Jose M Mato; Patricia Aspichueta; Ruben Nogueiras
Journal:  Hepatology       Date:  2020-11-13       Impact factor: 17.425

9.  Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.

Authors:  Ruben Nogueiras; Christelle Veyrat-Durebex; Paula M Suchanek; Marcella Klein; Johannes Tschöp; Charles Caldwell; Stephen C Woods; Gabor Wittmann; Masahiko Watanabe; Zsolt Liposits; Csaba Fekete; Ofer Reizes; Francoise Rohner-Jeanrenaud; Matthias H Tschöp
Journal:  Diabetes       Date:  2008-08-20       Impact factor: 9.461

10.  Ghrelin and Cannabinoid Functional Interactions Mediated by Ghrelin/CB1 Receptor Heteromers That Are Upregulated in the Striatum From Offspring of Mice Under a High-Fat Diet.

Authors:  Alejandro Lillo; Jaume Lillo; Iu Raïch; Cristina Miralpeix; Francesc Dosrius; Rafael Franco; Gemma Navarro
Journal:  Front Cell Neurosci       Date:  2021-12-09       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.